Atlas Trials

Cassava Sciences, Inc.

9 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Cassava Sciences, Inc.

RecordFirmDate
A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function (NCT06390410)Cassava Sciences, Inc.2024-06-26
Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects (NCT06195319)Cassava Sciences, Inc.2024-02-07
Open-label Extension for Phase 3 Clinical Trials of Simufilam (NCT05575076)Cassava Sciences, Inc.2022-11-07
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease (NCT05352763)Cassava Sciences, Inc.2022-05-12
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease (NCT05026177)Cassava Sciences, Inc.2021-11-18
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease (NCT04994483)Cassava Sciences, Inc.2021-11-03
Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers (NCT04932655)Cassava Sciences, Inc.2021-05-04
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients (NCT04388254)Cassava Sciences, Inc.2020-03-24
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients (NCT04079803)Cassava Sciences, Inc.2019-09-09

Track Cassava Sciences, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.